Halozyme Therapeutics Q3 EPS of $0.74 beats estimates by $0.23

Trending News 🌥️

Halozyme Therapeutics ($NASDAQ:HALO) is a biotechnology company that develops and commercializes innovative therapies based on its proprietary enzyme technology. The company’s products are used in a variety of indications, including cancer, diabetes, and autoimmune diseases. Halozyme’s third quarter non-GAAP EPS of $0.74 beats the consensus estimate by $0.23. This is a strong result for the company and underscores the potential of its innovative therapies.

Halozyme’s products are well positioned to help patients with a variety of serious diseases. We are confident in the company’s ability to continue to generate shareholder value.

Earnings

Halozyme Therapeutics reported their third quarter earnings for FY2022 and beat expectations by $0.23. In their earning report, they stated that their total revenue for the quarter was $487.5 million and their net income was $366.2 million. Compared to the previous year, this is a 10.0% increase in total revenue and a 9.1% decrease in net income. Halozyme Therapeutics has seen a significant increase in total revenue over the last three years, going from $267.6 million to $487.5 million.

Share Price

Halozyme’s stock opened at $46.3 and closed at $45.8, down by 1.0% from the prior closing price of $46.3.

VI Analysis

A company’s fundamentals reflect its long term potential. The VI app makes it easy to analyze a company’s financials to get an idea of its health. The VI Star Chart shows that HALOZYME THERAPEUTICS has an intermediate health score of 6/10 with regard to its cashflows and debt, meaning it is likely to safely ride out any crisis without the risk of bankruptcy. HALOZYME THERAPEUTICS is classified as a ‘gorilla’, a type of company that achieved stable and high revenue or earning growth due to its strong competitive advantage.

This makes it an attractive target for investors looking for a stable, high-growth company. HALOZYME THERAPEUTICS is strong in asset, growth, and profitability, and weak in dividend.

VI Peers

The Company’s enzyme-based product candidates target the tumor microenvironment, enabling the delivery of cancer drugs directly to the site of the tumor. Halozyme has four product candidates in clinical development, PEGPH20, Hylenex, HALO-102 and HALO-201. Keymed Biosciences Inc, Verona Pharma PLC, Xencor Inc are Halozyme’s competitors in the biopharmaceutical market.

– Keymed Biosciences Inc ($SEHK:02162)

Keymed Biosciences Inc is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics for the treatment of cancer and other serious diseases. The company’s market cap is 12.95B as of 2022 and has a ROE of -4.34%. Keymed Biosciences Inc’s products are designed to target key drivers of disease progression and to provide patients with new treatment options. The company’s lead product, KEY-184, is a first-in-class, orally-available small molecule inhibitor of the MDM2 oncoprotein.

– Verona Pharma PLC ($NASDAQ:VRNA)

Verona Pharma PLC is a pharmaceutical company that focuses on the development of drugs for the treatment of respiratory diseases. The company has a market cap of 790.27M as of 2022 and a Return on Equity of -28.69%. Verona Pharma PLC is headquartered in London, United Kingdom.

– Xencor Inc ($NASDAQ:XNCR)

Xencor Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. The company’s market cap as of 2022 is 1.64B with a ROE of 4.05%. Xencor is currently working on several clinical-stage programs including XmAb5871 for the treatment of B-cell malignancies, autoimmune diseases, and asthma.

Summary

Investing in Halozyme Therapeutics could be a wise move, as the company has a strong track record of beating earnings estimates. Given the company’s strong financials and favorable growth prospects, Halozyme Therapeutics could be a great addition to any portfolio.